TABLE 1.
Nucleus-targeting nanodrugs for enhancing PDT and PTT.
| Category | Nucleus-targeting strategies | Nanomaterials | Nucleus-targeting groups | Size (nm) | Therapy |
|---|---|---|---|---|---|
| Passive Nucleus-targeting nanodrugs | Size/hydrophilicity adjustment | CDcf Nasrin et al. (2020) | — | 8 | PDT |
| I-CDs @FA Xu et al. (2021) | 4.8(I-CDs) | PDT | |||
| Se/N-CDs Xu et al. (2020) | 3.6 ± 0.6 | PDT | |||
| D-KCD/A Hailong Yang et al. (2021) | ∼10 | PDT | |||
| Hf-HI-4COOH Jiang et al. (2020) | 30 | PTT | |||
| C-CD/TiO2 Phuong et al. (2020) | ∼25 (Z-CD) | PTT | |||
| Active Nucleus-targeting nanodrugs | Modification of nucleus-targeting groups | TPE-TTMN-TPA NPs (T4-NPs) Zhang et al. (2021) | TAT | 50–70 | PDT |
| Pd-TAT Gao et al. (2019) | TAT | 19.7 ± 1.9 | PTT | ||
| TID NPs Wan et al. (2020) | TAT | 108 | PTT/Chemotherapy (CT) | ||
| Ir-R/T NCs Wang et al. (2019) | TAT | <5 | PDT/Radio-therapy (RT) | ||
| CuS@MSN-TAT-RGD Li et al. (2018) | TAT | ∼40 | PTT | ||
| V2C-TAT@Ex-RGD Yu Cao et al. (2019) | TAT | 71 | PTT | ||
| GOPRD Tu et al. (2020) | CPPs | ∼20 | PTT/CT | ||
| DIR825@histone Guo et al. (2022) | Histone | ∼37.5 | PDT/CT | ||
| CACH-PEG Yang et al. (2018) | AS1411 | ∼65 (pH6.5) ∼70 (pH7.4) | PDT/CT | ||
| Light-controlled nuclear delivery | DTRCD Ziyang Cao et al. (2019) | TAT | 63.6 ± 9.6 | PDT/CT | |
| BCCGH Hua et al. (2018) | — | ∼7.9 | PDT/PTT | ||
| pnPNP Cheng et al. (2019a) | NLS | 157.6 ± 2.5 | PDT | ||
| ChiP-Exo Cheng et al. (2019b) | NLS | 132.6 | PDT | ||
| PPR NPs Zhu et al. (2018) | — | ∼75 | PDT | ||
| Ce6-C18-PEG/125I-Cur Shiyi Qin et al. (2021) | — | 10–30 | PDT |